CAR-T therapy in solid organ transplant recipients with treatment refractory posttransplant lymphoproliferative disorder

Dierickx, 2018, Post-transplantation lymphoproliferative disorders in adults, N Engl J Med., 378, 549, 10.1056/NEJMra1702693 Dharnidharka, 2016, Post-transplant lymphoproliferative disorders, Nat Rev Dis Primers., 2, 1, 10.1038/nrdp.2015.88 Peters, 2018, The changing epidemiology of posttransplant lymphoproliferative disorder in adult solid organ transplant recipients over 30 years: a single-center experience, Transplantation., 102, 1553, 10.1097/TP.0000000000002146 Trappe, 2017, Response to rituximab induction is a predictive marker in B-cell post-transplant lymphoproliferative disorder and allows successful stratification into rituximab or R-CHOP consolidation in an international, prospective, multicenter phase II trial, J Clin Oncol., 35, 536, 10.1200/JCO.2016.69.3564 Elstrom, 2006, Treatment of PTLD with rituximab or chemotherapy, Am J Transplant., 6, 569, 10.1111/j.1600-6143.2005.01211.x Choquet, 2006, Efficacy and safety of rituximab in B-cell post-transplantation lymphoproliferative disorders: results of a prospective multicenter phase 2 study, Blood., 107, 3053, 10.1182/blood-2005-01-0377 Trappe, 2012, Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial, Lancet Oncol., 13, 196, 10.1016/S1470-2045(11)70300-X Jhaveri, 2018, Chimeric antigen receptor T cell therapy and the kidney: what the nephrologist needs to know, Clin J Am Soc Nephrol., 13, 796, 10.2215/CJN.12871117 Neelapu, 2017, Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma, N Engl J Med., 377, 2531, 10.1056/NEJMoa1707447 Schuster, 2019, Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma, N Engl J Med., 380, 45, 10.1056/NEJMoa1804980 Sermer, 2019, CAR T-cell therapy: Full speed ahead, Hematol Oncol., 37, 95, 10.1002/hon.2591 Maude, 2018, Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia, N Engl J Med., 378, 439, 10.1056/NEJMoa1709866 Locke, 2019, Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial, Lancet Oncol., 20, 31, 10.1016/S1470-2045(18)30864-7 Hirayama, 2019, Toxicities of CD19 CAR-T cell immunotherapy, Am J Hematol., 94, S42, 10.1002/ajh.25445 Maude, 2014, Chimeric antigen receptor T cells for sustained remissions in leukemia, N Engl J Med., 371, 1507, 10.1056/NEJMoa1407222 Davila, 2014, Efficacy and toxicity management of 19–28z CAR T cell therapy in B cell acute lymphoblastic leukemia, Sci Transl Med., 6, 224ra225, 10.1126/scitranslmed.3008226 Lee, 2015, T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial, The Lancet., 385, 517, 10.1016/S0140-6736(14)61403-3 Gust, 2017, Endothelial activation and blood–brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells, Cancer Discov., 7, 1404, 10.1158/2159-8290.CD-17-0698 Alfreijat, 2013, Severe hepatitis associated with tocilizumab in a patient with rheumatoid arthritis, Rheumatology., 52, 1340, 10.1093/rheumatology/kes397 Decker, 2018, Tocilizumab and refractory Takayasu disease: four case reports and systematic review, Autoimmun Rev., 17, 353, 10.1016/j.autrev.2017.11.026 Gupta, 2020, Acute kidney injury and electrolyte abnormalities after chimeric antigen receptor T-cell (CAR-T) therapy for diffuse large B-cell lymphoma, Am J Kidney Dis., 76, 63, 10.1053/j.ajkd.2019.10.011